Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cartesian Therapeutics is a biotech company developing mRNA cell therapies for autoimmune diseases. Its lead product, Descartes-08, is an autologous mRNA CAR-T targeting BCMA, designed to treat conditions like myasthenia gravis and systemic lupus erythematosus. The company leverages proprietary technology to create outpatient, repeat-dosed treatments that aim to provide deep, durable, and safer immune modulation without pre-treatment chemotherapy.
This description was generated via AI from an annual report. Updated about 1 year ago.